ID

43022

Beskrivning

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication; ODM derived from: https://clinicaltrials.gov/show/NCT01805531

Länk

https://clinicaltrials.gov/show/NCT01805531

Nyckelord

Versioner (2)
  1. 2019-08-07 2019-08-07 -
  2. 2021-09-17 2021-09-17 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

17 september 2021

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Atrial Fibrillation NCT01805531

Engelsk

Eligibility Atrial Fibrillation NCT01805531

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation
Beskrivning

Age | Atrial Fibrillation

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0004238
who are treated with vitamin k antagonists (vka) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
Beskrivning

Treatment with Vitamin K antagonist | Problem Duration

Datatyp

boolean

Alias
UMLS CUI [1]
C1096489
UMLS CUI [2,1]
C0033213
UMLS CUI [2,2]
C0449238
who start treatment with rivaroxaban to prevent stroke or non-cns (central nervous system) systemic embolism
Beskrivning

rivaroxaban | Treatment Preventing Cerebrovascular accident | Treatment Preventing SYSTEMIC ARTERIAL EMBOLISM | Exception Central Nervous System

Datatyp

boolean

Alias
UMLS CUI [1]
C1739768
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1292733
UMLS CUI [2,3]
C0038454
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C1292733
UMLS CUI [3,3]
C0149876
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C3714787
with anticoagulation therapy planned for at least 6 months
Beskrivning

Anticoagulation Therapy Planned

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0003281
UMLS CUI [1,2]
C1301732
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
contra indication to the use of xarelto as described in the summary of product characteristics (smpc); key contra indications are:
Beskrivning

Medical contraindication Xarelto

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C3159309
hypersensitivity to the active substance or to any of the excipients listed in smpc section 6.1.
Beskrivning

Hypersensitivity Xarelto | Hypersensitivity Xarelto Excipient

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C3159309
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C3159309
UMLS CUI [2,3]
C0015237
lesion or condition at significant risk of major bleeding
Beskrivning

Lesion At risk Hemorrhage Major | Condition At risk Hemorrhage Major

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0019080
UMLS CUI [1,4]
C0205164
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0019080
UMLS CUI [2,4]
C0205164
concomitant treatment with any other anticoagulant agent
Beskrivning

Anticoagulants Other

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0003280
UMLS CUI [1,2]
C0205394
clinically significant active bleeding
Beskrivning

Hemorrhage

Datatyp

boolean

Alias
UMLS CUI [1]
C0019080
hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c
Beskrivning

Liver disease Associated with Blood Coagulation Disorders | Bleeding risk | Patients Cirrhotic Child-Pugh Classification

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023895
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0005779
UMLS CUI [2]
C3251812
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C0439686
UMLS CUI [3,3]
C4050412
pregnancy and breast feeding
Beskrivning

Pregnancy | Breast Feeding

Datatyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Tillbaka till toppen

Similar models

Eligibility Atrial Fibrillation NCT01805531

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | Atrial Fibrillation
Item
female and male subjects ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation
boolean
C0001779 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
Treatment with Vitamin K antagonist | Problem Duration
Item
who are treated with vitamin k antagonists (vka) with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
boolean
C1096489 (UMLS CUI [1])
C0033213 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
rivaroxaban | Treatment Preventing Cerebrovascular accident | Treatment Preventing SYSTEMIC ARTERIAL EMBOLISM | Exception Central Nervous System
Item
who start treatment with rivaroxaban to prevent stroke or non-cns (central nervous system) systemic embolism
boolean
C1739768 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0038454 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C1292733 (UMLS CUI [3,2])
C0149876 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C3714787 (UMLS CUI [4,2])
Anticoagulation Therapy Planned
Item
with anticoagulation therapy planned for at least 6 months
boolean
C0003281 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Xarelto
Item
contra indication to the use of xarelto as described in the summary of product characteristics (smpc); key contra indications are:
boolean
C1301624 (UMLS CUI [1,1])
C3159309 (UMLS CUI [1,2])
Hypersensitivity Xarelto | Hypersensitivity Xarelto Excipient
Item
hypersensitivity to the active substance or to any of the excipients listed in smpc section 6.1.
boolean
C0020517 (UMLS CUI [1,1])
C3159309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C3159309 (UMLS CUI [2,2])
C0015237 (UMLS CUI [2,3])
Lesion At risk Hemorrhage Major | Condition At risk Hemorrhage Major
Item
lesion or condition at significant risk of major bleeding
boolean
C0221198 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0019080 (UMLS CUI [1,3])
C0205164 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0019080 (UMLS CUI [2,3])
C0205164 (UMLS CUI [2,4])
Anticoagulants Other
Item
concomitant treatment with any other anticoagulant agent
boolean
C0003280 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Hemorrhage
Item
clinically significant active bleeding
boolean
C0019080 (UMLS CUI [1])
Liver disease Associated with Blood Coagulation Disorders | Bleeding risk | Patients Cirrhotic Child-Pugh Classification
Item
hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with child pugh b and c
boolean
C0023895 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0005779 (UMLS CUI [1,3])
C3251812 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C0439686 (UMLS CUI [3,2])
C4050412 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
pregnancy and breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial